ATLANTA--(BUSINESS WIRE)--Ambit Biosciences announced today that the company presented data from its ongoing Phase I clinical evaluation of AC220, a small-molecule class III receptor tyrosine kinase (RTK) inhibitor for the treatment of acute myeloid leukemia (AML). Data were presented in a poster titled, “AC220 Preclinical Profile and Early Human Experience in Relapsed or Refractory Acute Myeloid Leukemia,” at the 49th American Society of Hematology (ASH) Annual Meeting and Exposition on Saturday, December 8 at 5:30 p.m. Eastern.
